VIO (Visudyne In Occult) Study

Who is the sponsor?
QLT and Novartis Opthalmics

Who are the patients?
Male or female over the age of fifty years with AMD The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.

How long are the eligible patients enrollment?
Assessments will be done every three months for a period of 24 months

When did participation agreement start at our site?
Nov 11, 2002

What is the enrollment goal for the sponsor?
Three hundred and sixty patients nation wide.

Is the enrollment still open?
No. This study is now closed

What is this study investigating?
This is a Phase III, multicenter, randomized, double-masked, placo-controlled study to demonstrate that VisudyneTM therapy in patients with “occult type” wet AMD, significantly reduce the risk of vision loss compared with placebo (sham treatment).

How is the treatment administered?
IV injection of VisudyneTM with PDT treatment or placebo